This was a pharmacovigilance (drug safety) study using the U.S. FDA Adverse Event Reporting System (FAERS) database. Researchers looked at reports involving GLP-1 receptor agonists, including semaglutide, and focused on menstrual and reproductive-related adverse events. They used disproportionality analysis (signal detection) to see whether certain menstrual problems were reported more often with specific GLP-1 drugs than with other medications. The primary endpoint was identifying which GLP-1 agents showed the strongest “signal” for menstrual adverse events.
Among GLP-1 receptor agonists, semaglutide showed the broadest and strongest signal for menstrual-related adverse events in FAERS. Signals suggest higher-than-expected reporting of menstrual issues, such as abnormal bleeding or cycle disturbances, compared with many other drugs. This type of analysis identifies reporting ‘signals’ but does not provide actual incidence rates or confirm causation. The authors interpret this as a safety signal that merits closer monitoring and further controlled studies.
This study uses spontaneous FAERS reports, which are voluntary, incomplete, and prone to under- and over-reporting; they cannot provide true risk or incidence estimates. There are no control groups, no reliable denominators (number of exposed patients), and limited clinical detail about weight changes, baseline cycle patterns, contraception, PCOS, or other conditions affecting menstruation. A reporting “signal” does not prove that semaglutide causes menstrual problems; it only suggests an association worth further study. The findings may be influenced by semaglutide’s high use, media attention, and off-label weight-loss use in reproductive-age women, and the study does not define which women (by age, diagnosis, dose, or duration) are at highest risk.
For clinicians, this study raises a plausible safety signal that semaglutide may be associated with menstrual disturbances more often than some other GLP-1 drugs. However, FAERS data are subject to major biases: underreporting, stimulated reporting (media/marketing effects), incomplete clinical context, and lack of denominators or controls. Weight loss itself, changes in insulin resistance, rapid shifts in adipokines, and improvements or disruptions in HPO-axis signaling can all alter cycles and may explain part of the signal. The findings fit with scattered case reports and patient anecdotes about cycle changes on GLP-1s, but conflict with the limited formal trial data where menstrual outcomes are rarely systematically captured; this gap underscores the need for prospective, cycle-aware research.
Explain to patients that GLP-1 medications, especially semaglutide, may be associated with cycle changes, though we do not yet know how often or why. Encourage detailed cycle charting (bleeding days, flow intensity, pain, ovulation signs, and premenstrual symptoms) before and after starting a GLP-1 drug. In a restorative framework, interpret new menstrual changes as a signal to reassess metabolic status (insulin, glucose, lipids), thyroid function, iron stores, and inflammatory markers, rather than dismissing them as minor side effects. Urgently refer for evaluation if a patient reports very heavy bleeding, soaking pads hourly, bleeding between periods, severe new pelvic pain, or prolonged absence of periods when pregnancy is possible.
This research looked at safety reports sent to the FDA from people taking GLP-1 weight-loss and diabetes medicines. It found that semaglutide had the strongest pattern of reported period changes compared with other drugs in its class. This does not prove that semaglutide definitely harms your cycle, but it suggests that period changes on this medicine are common enough to be noticed in large safety databases. If you are trying to conceive or protect your fertility, treat new cycle changes as a clue: track your periods, note any heavy bleeding or missed cycles, and work with a clinician to check for underlying issues like hormone shifts, rapid weight changes, blood-sugar changes, thyroid problems, or anemia rather than assuming the changes are harmless.
Consider menstrual changes as a potential class effect of GLP-1 RAs, with semaglutide showing the strongest FAERS signal in this analysis. In restorative practice, baseline and follow-up cycle charting (length, luteal phase, ovulation biomarkers, flow characteristics, dysmenorrhea, intermenstrual bleeding) should be routine when initiating GLP-1s in reproductive-age patients. If menstrual disturbance emerges, evaluate for HPO-axis disruption, rapid adiposity loss, relative energy deficiency, insulin and androgen shifts (especially in PCOS), thyroid function, prolactin, iron status, and endometrial pathology as indicated. Counsel on potential fertility implications: possible changes in ovulation timing, luteal adequacy, and bleeding patterns; review contraception needs, peri-conception use, and preconception washout recommendations. Recognize FAERS limitations: treat these as hypothesis-generating data and integrate with individual patient context, prioritizing shared decision-making and ongoing monitoring over abrupt discontinuation solely based on this signal.
Educational insights, not a diagnosis or individualized treatment advice. Discuss findings with your own clinician. Visit Reproductive Health Insights to explore fertility resources.